Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
Rhea-AI Summary
Zevra Therapeutics (Nasdaq: ZVRA) will report fourth quarter and full year 2025 corporate and financial results on Monday, March 9, 2026 after market close, followed by a conference call and audio webcast at 4:30 p.m. ET. The live webcast link and replay will be available on the company’s Investor Relations Events & Presentations page.
Telephone dial-ins include a U.S. number and an international number; a replay will be available for 90 days beginning about 5:30 p.m. ET.
Positive
- None.
Negative
- None.
News Market Reaction – ZVRA
In the Mar 2 session, ZVRA gained 1.79%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 results | Positive | -9.7% | Reported strong Q3 2025 revenue and narrowed net loss with solid cash. |
| Oct 27 | Q3 call details | Neutral | +4.4% | Announced timing and access details for Q3 2025 earnings call. |
| Aug 12 | Q2 2025 results | Positive | -19.8% | Reported strong Q2 2025 revenue and cash inflow from voucher sale. |
| Aug 04 | Q2 call details | Neutral | +1.3% | Scheduled Q2 2025 financial results release and webcast logistics. |
| May 13 | Q1 2025 results | Positive | +3.4% | Reported strong Q1 2025 revenue and reduced net loss with solid cash. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-result releases with strong metrics have previously seen negative one-day moves, while prior earnings call scheduling releases showed modest positive reactions.
Across recent earnings-related events, Zevra reported growing revenues and a strengthened balance sheet. Q1 2025 delivered $20.4 million in net revenue and a reduced net loss of $3.1 million. Q2 2025 showed net revenue of $25.9 million, boosted by a $150.0 million Priority Review Voucher sale and net income of $74.7 million. Q3 2025 net revenue reached $26.1M with MIPLYFFA contributing $22.4M, and cash was $230.4M as of September 30, 2025. Today’s Q4/FY 2025 call notice follows this sequence of quarterly updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the fourth quarter and full year 2025 on Monday, March 9, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.
A link to the audio webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.
To join via telephone, please use the following dial-in information:
- (800) 579-2543 (United States)
- +1 (785) 424-1789 (International)
- Conference ID: ZVRAQ425
A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases. The company’s commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disorder, provides a strong corporate foundation and validates its ability to advance therapies. In addition, the company is broadening access through geographic expansion opportunities and has a pipeline of rare disease programs. Zevra is a patient-centric organization guided by our values of accountability, integrity, innovation and courage, with the goal of creating long-term value for patients, partners, and shareholders.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025, filed on November 5, 2025, as well as Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
